UTHR insider notice: 90,000 shares ($40.78M) to be sold on 10/06/2025
Rhea-AI Filing Summary
United Therapeutics (UTHR) filed a Form 144 reporting a proposed sale of 90,000 common shares, to be executed through Morgan Stanley Smith Barney LLC on
The notice also discloses multiple Rule 10b5-1 sales attributed to Michael Benkowitz during September 2025 totaling several transactions (examples: 7,875 and 14,625 share blocks) with gross proceeds reported per trade. The filer affirms no undisclosed material nonpublic information and includes the standard signature/attestation language required by the form.
Positive
- Transaction transparency: Form 144 discloses the full sale amount of 90,000 shares and
$40,776,300.00 aggregate market value - Use of 10b5-1 plans for prior September
09/2025 sales indicates pre-arranged disposition consistent with compliance practices
Negative
- Large block relative to float: 90,000 shares represent a notable package against 45,226,262 outstanding shares
- Concentration of sales by an insider in a short period (
09/2025 trades plus this10/06/2025 sale) could increase short-term supply pressure
Insights
TL;DR: An insider plans a large post-exercise sale of newly exercised options alongside recent 10b5-1 trades.
The filing reports the proposed sale of 90,000 shares acquired by exercise of stock options on
These shares carry an aggregate market value of
Key dependencies include the execution price and timing on
TL;DR: The Form 144 is procedural and includes the standard attestation against undisclosed material information.
The notice uses the required attestation language that the selling person does not possess undisclosed material adverse information as of the signatory date. The sale is routed through Morgan Stanley Smith Barney LLC and is designated for NASDAQ execution on
From a governance perspective, the presence of documented 10b5-1 sales in